TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06658301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric push up exercises
Description: The subjects will starts with push-up position with hands on the floor, place slightly wider than shoulder width apart and their feet together. Keeping their back flat, slowly lower the body toward the ground. Then in one explosive movement, push-up and away from the floor as quickly as possible, bring their hands off the floor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: swiss ball push up exercises
Description: . The subjects will start with kneeling position so that they will face the ball. Place their hands on top of the ball so that they can bend their elbows towards the body. Straight the legs out and raise themselves slightly higher so that they can be on their toes. Stay in neutral position. Straighten their arms at the elbows, so that they can push themselves up from the ball.
Study: NCT06669416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste Alteration Self-Assessment
Description: The nurse-led intervention involves using a valid/reliable TA assessment tool (Chemotherapy-induced Taste Alterations Scale (CiTAS) and teaching the patient to select assessment-driven interventions to manage TA symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste Alternation Self-Management
Description: The nurse-led intervention involves teaching the patient to use the assessments and the evidence-based Patient Education Sheet to select assessment-driven interventions to manage their symptoms. Data will be collected about the specific actions prescribed in the teaching tool and to identify which interventions were used and their overall impact.
Study: NCT05256290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-1535 monotherapy
Description: BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-1535 monotherapy
Description: BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-1535 monotherapy
Description: BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDTX-1535 monotherapy
Description: BDTX-1535 is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Study: NCT05599100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-Caregivers Virtual Training & Follow-up (STAR-VTF)
Description: For 6-8 weeks, caregivers will complete online training modules asynchronously. Caregivers will be instructed to complete one module per week. The content of the modules is as follows: Module 1 introduces caregivers to the behavioral treatment of dementia, realistic expectations, and effective communication; Module 2 covers the ABC (antecedents, behaviors, consequences) approach to problem-solving, including rationale and development of an ABC plan; Module 3 instructs caregivers to review the ABC plan and revise as needed; Module 4 covers pleasant events and managing negative thinking; Module 5 instructs caregivers to review the ABC plan, pleasant activities schedule, and to revise as needed; Module 6 covers coping with caregiving and maintaining gains. Each module takes about 45 minutes to complete. The modules use text, pictures, and illustrations with a voiceover presentation. Caregivers will receive the online training modules in their preferred language (English or Spanish).
Study: NCT05870865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN008
Description: ASN008 topical gel applied twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN008
Description: ASN008 topical gel applied twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN008
Description: ASN008 topical gel applied twice daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ASN008 Matching Vehicle
Description: The ASN008 matching vehicle formulation matches the formulation of each ASN008 topical gel dose, but contains no ASN008.
Study: NCT06022926

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warmed with electric blankets
Description: warmed with electric blankets

Intervention type: OTHER
Group type: OTHER
Intervention: patients without warming
Description: patients without warming: no electric blanket will be used, and no heating will be applied to this group of patients.
Study: NCT04585958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study: NCT06017973

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan including arterial spin labelling of the brain
Description: Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan including arterial spin labelling of the brain
Description: Arterial Spin Labelling sequence, T2-weighted FLAIR images and T1-weighted images and diffusion weighted imaging sequence will be recorded

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT perfusion scan of the brain
Description: Siemens Naeotom Alpha with quantum technology (photon-counting)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT perfusion scan of the brain
Description: Siemens Naeotom Alpha with quantum technology (photon-counting)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET scan of the brain
Description: An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET scan of the brain
Description: An FDG-PET scan will be acquired on a GE Signa 3T PET-MR scanner. FDG-PET images will be assessed for focal hypermetabolism, including semiquantitative analysis of the maximal standard uptake value (SUVmax) relative to the SUVmax of the pons (SUVr pons)
Study: NCT05694182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other: Oral superfruits supplement
Description: The supplement contain superfruits that are beneficial for human health
Study: NCT05107674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-1607
Description: Oral NX-1607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV
Study: NCT06251115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY-1-T
Description: QY-1-T is a TCR-T drug targeting HBV-related HCC
Study: NCT05394857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 subcutaneously
Study: NCT06253871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IAM1363
Description: Oral, immediate release capsules of IAM1363
Study: NCT06626269

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: In cohort A: 3 or 4 blood samples (for plasma and PBMC collection) : at baseline (before immunotherapy initiation); at 3 months ; at 12 months; on case of severe or unexpected toxicity.~In cohort B: 3 blood sampes (for plasma and PBMC collection): at baseline (before treatment initiation); at 3 months ; at 12 months~In cohort C: 2 blood samples (for plasma and PBMC collection) : at baseline (at the time of surgery); at 3 months (after surgery)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor tissue
Description: Cohort A and B: 1 tumor block in paraffin at diagnosis + 1 tumor block in paraffin at progression (optional) Cohort C: Fresh tumoral tissue fragments to be recovered in the operating room and sent to the ITAC platform for TIL and CAF + 1 tumor block in paraffin at time of surgery.
Study: NCT06625528

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: open flap debridement
Description: does lyophilized platelet rich fibrin combined with open flap debridement or combination of open flap debridement, lyophilized platelet rich fibrin and nano-crystalline hydroxyapatite bone substitute can add benefits to open flap debridement alone or not
Study: NCT05923008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI130
Description: Subjects will receive IBI130 until unacceptable toxicity, disease progression, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or for a maximum of 24 months of treatment, whichever occurs first.
Study: NCT05485129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIORICS
Description: Wearing BIORICS in their ear and perform mental arrhythmic test, relaxation exercises and Stroop test
Study: NCT05192707

Intervention type: DIAGNOSTIC_TEST
Intervention: TcPO2 measurement on the upper limb
Description: Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: TcPO2 measurement on the upper limb
Description: Measurement of the transcutaneous Oxygen Pressure in the upper limb of 30 healthy volunteers and of at least 30 patients.
Study: NCT06631976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of Depo-Medrol® injection
Description: 1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve block with 4ml of 2% lidocaine
Description: Nerve block with 4ml of 2% lidocaine around the suprascapular nerve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropocells® PRP injection
Description: Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
Study: NCT06631664

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional physical therapy
Description: Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
Study: NCT05800444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Oral administration as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Oral administration as tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Oral administration as tablet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration as tablet.
Study: NCT04495452

Intervention type: DRUG
Intervention: Fentanyl Drug Administration
Description: Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
Study: NCT05270863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™ PF
Description: A single drop in each eye at a visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbachol PF
Description: A single drop in each eye at a visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate
Description: A single drop in each eye at a visit.
Study: NCT06698939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORKA-001
Description: ORKA-001 is supplied as sterile solution to be administered by SC injection
Study: NCT05238948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Substrate of CYP3A4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-506
Description: Perpetrator of CYP3A4
Study: NCT05047640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Description: Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78436735 Vaccine
Description: Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
Study: NCT05344716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Intraurethral and vaginal laser treatment
Study: NCT06698939

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution to be administered at a matching volume by SC injection
Study: NCT06633393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System
Description: At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback on Ophthalmic Examinations
Description: At baseline and six months, participants will be provided with the results of their ophthalmic examinations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback on Ophthalmic Examinations
Description: At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
Study: NCT06693362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Study: NCT06287437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 placebo
Description: HRS9531 placebo low frequency injection for 12 weeks.
Study: NCT05551702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-txt
Description: Cognitive Behavioral Therapy delivered via automated text messaging.
Study: NCT05732272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
Study: NCT06693362

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary.
Study: NCT06702618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule+Fulvestrant Injection
Description: TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
Study: NCT06717659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic supplementation intervention
Description: probiotic supplementation will be administered, while participants continue undergoing routine pulmonary rehabilitation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard pulmonnary rehabilitation
Description: undergo routine pulmonary rehabilitation without probiotics intervention